# Creative Medical Technology Holdings, Inc.: overview CELZ · Nasdaq · CIK 1187953 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/celz.md) · [Financials](/companies/celz/financials.md) · [Filings](/companies/celz/filings.md) · [Insiders](/companies/celz/insiders.md) Latest reported revenue: [$0](/filings/0001477932-26-004779.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:Revenues, accession 0001477932-26-004779). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | [0.0](/filings/0001477932-25-007978.md) | [3,000 d](/filings/0001477932-26-001517.md) | [3,000](/filings/0001477932-26-002893.md) | [0.0](/filings/0001477932-26-004779.md) | [0.0](/filings/0001477932-25-007978.md) | [3,000 d](/filings/0001477932-26-001517.md) | [0.0](/filings/0001477932-26-002893.md) | [0.0](/filings/0001477932-26-004779.md) | | Gross margin | % | not reported | [60.0% d](/filings/0001477932-26-001517.md) | [60.0%](/filings/0001477932-26-002893.md) | not reported | not reported | [66.9% d](/filings/0001477932-26-001517.md) | not reported | not reported | | Operating margin | % | not reported | [(62857.8%) d](/filings/0001477932-26-001517.md) | [(55349.3%)](/filings/0001477932-26-002893.md) | not reported | not reported | [(64859.4%) d](/filings/0001477932-26-001517.md) | not reported | not reported | | Net margin | % | not reported | [(61802.5%) d](/filings/0001477932-26-001517.md) | [(54603.2%)](/filings/0001477932-26-002893.md) | not reported | not reported | [(62922.5%) d](/filings/0001477932-26-001517.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.75)](/filings/0001477932-25-007978.md) | not reported | [(0.83)](/filings/0001477932-26-002893.md) | [(0.48)](/filings/0001477932-26-004779.md) | [(0.48)](/filings/0001477932-25-007978.md) | not reported | [(0.38)](/filings/0001477932-26-002893.md) | [(0.41)](/filings/0001477932-26-004779.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [87.8](/filings/0001477932-23-002123.md) | [88.6](/filings/0001477932-24-001431.md) | [9.0](/filings/0001477932-25-001736.md) | [11.0](/filings/0001477932-26-001517.md) | [6.0](/filings/0001477932-26-001517.md) | | Gross margin | % | [45.4%](/filings/0001477932-23-002123.md) | [67.8%](/filings/0001477932-24-001431.md) | [60.0%](/filings/0001477932-25-001736.md) | [60.0%](/filings/0001477932-26-001517.md) | [63.4%](/filings/0001477932-26-001517.md) | | Operating margin | % | [(3562.2%)](/filings/0001477932-23-002123.md) | [(11562.5%)](/filings/0001477932-24-001431.md) | [(62445.9%)](/filings/0001477932-25-001736.md) | [(52216.9%)](/filings/0001477932-26-001517.md) | [(102380.2%)](/filings/0001477932-26-001517.md) | | Net margin | % | [21892.8%](/filings/0001477932-23-002123.md) | [(11449.3%)](/filings/0001477932-24-001431.md) | [(58739.7%)](/filings/0001477932-25-001736.md) | [(49940.7%)](/filings/0001477932-26-001517.md) | [(99916.8%)](/filings/0001477932-26-001517.md) | | Diluted EPS | $ per share | [5.61](/filings/0001477932-23-002123.md) | [(0.93)](/filings/0001477932-23-002123.md) | [(3.76)](/filings/0001477932-25-001736.md) | [(3.71)](/filings/0001477932-26-001517.md) | [(2.52)](/filings/0001477932-26-001517.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/celz/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Hudson Bay Capital Management LP](/funds/1393825.md) | 2026-06-30 | $196.0k | 135,170 | | New +135,170 | | [Anson Funds Management LP](/funds/1491072.md) | 2026-06-30 | $153.0k | 105,549 | | New +105,549 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $60.9k | 42,000 | | New +42,000 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $38.5k | 26,559 | | Added +12,299 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $37.4k | 25,799 | | Reduced −12,491 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $29.5k | 20,350 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $8.0k | 5,518 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $7.0k | 4,853 | | Added +2,761 | | [Global Retirement Partners, LLC](/funds/1749744.md) | 2026-06-30 | $6.0k | 4,118 | | Not compared | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $3.0k | 2,061 | | Added +2,060 | ## Recent filings [All 403 filings](/companies/celz/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-01 | 21:00 ET | [SCHEDULE 13D](/filings/0001477932-26-005959.md) | Ownership report, active investor | 0001477932-26-005959 | | 2026-09-25 | 21:00 ET | [8-K](/filings/0001477932-26-005805.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001477932-26-005805 | | 2026-08-31 | 20:05 ET | [8-K](/filings/0001477932-26-005329.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001477932-26-005329 | | 2026-08-07 | 21:23 ET | [10-Q](/filings/0001477932-26-004779.md) | Quarterly report, period 2026-06-30 | 0001477932-26-004779 | | 2026-07-14 | 20:00 ET | [DEF 14A](/filings/0001477932-26-004302.md) | Proxy statement, period 2026-08-28 | 0001477932-26-004302 | | 2026-07-02 | 20:15 ET | [8-K](/filings/0001477932-26-004165.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001477932-26-004165 | | 2026-06-26 | 20:16 ET | [S-1/A](/filings/0001477932-26-004044.md) | Registration statement, amended | 0001477932-26-004044 | | 2026-06-25 | 20:06 ET | [S-1](/filings/0001477932-26-004010.md) | Registration statement | 0001477932-26-004010 | | 2026-05-08 | 20:45 ET | [10-Q](/filings/0001477932-26-002893.md) | Quarterly report, period 2026-03-31 | 0001477932-26-002893 | | 2026-04-24 | 20:45 ET | [10-K/A](/filings/0001477932-26-002534.md) | Annual report, amended, period 2025-12-31 | 0001477932-26-002534 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001477932-26-001517.md), filed Mar 20, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e95344b9-7176-4ebb-95a3-ffacaea5261b) ## About the filer - CIK: 1187953 - Tickers: CELZ - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.